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I. INTRODUCTION
The consequences of unfettered scientific research have long provided the
thematic basis for numerous science fiction novels, including such classics as
Mary Shelley's Frankenstein' and H. G. Wells' The Island of Dr. Moreau.2 In
Frankenstein, Dr. Frankenstein assembles a monster using parts of corpses and
brings it to life.3 While in The Island of Dr. Moreau, Dr. Moreau's experiments
turn animals into strange human-like creatures. Both Dr. Frankenstein and Dr.
Moreau are eventually slain by the creatures they created when it escapes out of
their control.5 With modern-day advances in scientific and medical research, the
proposition for which these novels stand for-mainly that scientific research, if
left unchecked, could have horrible and devastating consequences-no longer
exists only in the world of science fiction. Some recent advances that seem to
have come straight out of a science fiction novel include xenotrasplantation,6
mechanical transplants,7  and reproductive cloning.! Just as the novels
Frankenstein and The Island of Dr. Moreau evoked fear of science gone out of
control, these modern-day advances raise fears and concerns about the possible
ramifications of unchecked scientific research. 9 In no other scientific area today
are these fears and concerns so as in the area of human embryonic stem cell
research."°
* J.D. candidate, University of the Pacific, McGeorge School of Law, to be conferred 2008. I would like
to extend my deepest thanks to my family for their love, support, and encouragement. I would also like to thank
my husband, Hamlet Medina, for his unwavering support in all that I do. Special thanks to my faculty advisor,
Professor Jed Scully, and to those who helped me with the preparation of this Comment. This Comment is in
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1. See generally MARY WOLLSTONECRAFT SHELLY, FRANKENSTEIN (Maurice Hindle ed., Penguin
Group 2003) (1831).
2. See generally H. G. WELLS, THE ISLAND OF DR. MOREAU (Dover Publications 1996) (1896).
3. SHELLY, supra note 1.
4. WELLS, supra note 2.
5. SHELLY, supra note I; WELLS, supra note 2.
6. PBS.org, A History of Xenotrasplantation Experiments, http://www.pbs.org/wgbh/pages/frontline/
shows/organfarm/etc/cron.html (last visited Feb. 6, 2007) (defining Xenotransplantation as the transplantation
of tissues from one species to another, such as the transplantation of pig heart valves into humans).
7. CNN.com, Patient Gets First Totally Implanted Artificial Heart, July 3, 2001, http://archives.cnn.
coml200llHEALTHlconditions/07/03/artificial.heartl (describing how a patient received the first completely
implanted artificial heart that totally replaced the function of the human heart).
8. Human Genome Program, Cloning Fact Sheet, http://www.oml.gov/sci/techresources/Human-
Genome/elsi/cloning.shtml (last visited Mar. 8, 2008) (defining reproductive cloning as the technology used to
generate an animal that has the same nuclear DNA as another currently or previously existing animal.) "In a
process called somatic cell nuclear transfer, scientists transfer genetic material from the nucleus of a donor adult
cell to an egg whose nucleus, and thus its genetic material, has been removed. The reconstructed egg containing
the DNA from a donor cell must be treated with chemicals or electric current in order to stimulate cell division.
Once the cloned embryo reaches a suitable stage, it is transferred to the uterus of a female host where it
continues to develop until birth. Id.
9. See AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, STEM CELL RESEARCH AND
APPLICATIONS: FINDINGS AND RECOMMENDATIONS (Nov. 1999), available at http://www.aaas.orglspp/sfrl/
projects/stemlfindings.shtml. [Hereinafter AAAS].
10. See Eleni Berger, Research Avenue Adds Fuel to Stem Cell Controversy, CNN.com, July 11, 2001,
Global Business & Development Law Journal / Vol. 21
This Comment compares the current U.S. policy regulating human embry-
onic stem cell research to that of Singapore, and how the disparities in their
policies are leading to two different results on the technological, the economical,
and the medical development within these two countries. This Comment focuses
on the effects of the current U.S. policy regulating stem cell research on the U.S.
biotechnology industry, economy, and public health. Part II discusses the current
U.S. policy and Singapore laws on human embryonic stem cell research. Part III
provides a brief background to the science of stem cell research and the benefits
of the research. Part IV focuses on the ethical debate surrounding stem cell
research. Part V discusses the effects of the U.S. policy on the biotechnology
industry, the U.S. economy, and the health and welfare of the American people.
Part VI explores possible solutions to some of the issues that are raised by the
stem cell debate and considers how the United States may benefit from following
a successful model such as the one employed by Singapore. Finally, Part VII
concludes that the United States will be economically and technologically
disadvantaged if it does not fund stem cell research and participate in the drafting
of international guidelines regulating stem cell research.
II. HUMAN EMBRYONIC STEM CELL RESEARCH LAWS
A. U.S. Policy
On August 9, 2001, President George W. Bush announced that he was
prohibiting the use of federal funds for human embryonic stem cell research
because of moral concerns over the destruction of human embryos." The current
policy continues to permit federal funding for research that uses stem cell lines
derived on or before August 9, 2001, as wells as cord blood stem cells, adult stem
cells, and animal stem cells.' 2 However, it prohibits the use of federal funds for
the derivation or use of stem cell lines from newly destroyed embryos, the
creation of any human embryos for research purposes, or the cloning of human
embryos for any purpose."
President Bush's policy did not directly affect privately funded research,
although it indirectly has had a substantial impact on it.'4 The current federal
funding policy requires that any researcher conducting research on ineligible
http://archives.cnn.com/2001/HEALTH/07/1 I/stem.cell. fact/.
11. President George W. Bush, Remarks by the President on Stem Cell Research to the Nation (Aug. 9,
2001) (transcript available at http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html).
12. Id.
13. Press Release, The White House, Office of the Press Secretary, Fact Sheet: Embryonic Stem Cell
Research (Aug. 9, 2001), available at http://www.whitehouse.gov/news/releases/2001/08/20010809-1 .html (last
visited Oct. 22, 2006).
14. Paul Jacobs, Veto Rattles Stem-Cell Efforts, San Jose Mercury News, July 20, 2006, http://www.
mercurynews.com/mld/mercurynews/news/local/15080713.htm?source=yahoodist&amp;content=sj mnews.
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stem cell lines use facilities that do not receive federal funding.'" Such a
requirement prevents researchers from using laboratories and facilities that
already exist, leading to a costly duplication of laboratories and equipment.16 The
federal policy has impeded progress because science advances when researchers
are able to share their findings with each other.' 7 The federal policy prevents
federally-funded researchers from sharing their data and findings with
researchers working on ineligible stem cell lines and vice versa, impeding the
spread of new developments and findings in the field of stem cell research.'"
To date, there is no federal law on stem cell research.' 9 The U.S. Congress
has considered several bills regarding stem cell research, but to date has only
passed two of those bills.2° The first bill, which would have lifted the restrictions
on federal funding for stem cell research, was vetoed by President Bush in July
2006.2
The second bill, which was similar to the first, passed in January 2007 by a
vote of 253 to 174.22 However, this vote also fell short of the two-thirds needed to
override the Presidential veto.23
As a result, regulation of stem cell research has been largely left to the
individual states.24 States, such as Connecticut, 25 New Jersey,26 and Massachu-
15. Id.
16. Id.
17. Id.
18. Id.
19. Jonathan Todres & Pamela L. Marcogliese, International Health Law, 39 INT'L LAW. 503, 510
(2005).
20. THE NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES,
STEM CELL INFORMATION: CONGRESSIONAL LEGISLATION, http://stemcells.nih.gov/policy/Iegislation.asp (last
visited Feb. 15, 2007).
21. David Greene, Bush Vetoes Bill to Expand Stem Cell Research, NPR, July 19, 2006, http://www.
npr.org/templates/story/story.php?storyld=5252449.
22. CNN.com, '100 Hours': House Passes Stem-Cell Bill Despite Veto Threat, Jan. 11, 2007,
http://www.cnn.com/2007IPOLITICS/01/11/stem.cell.ap/index.html.
23. Id.
24. Todres & Marcogliese, supra note 19.
25. Connecticut Department of Public Health Office of Research and Development, http://www.
dph.state.ct.us/StemCell/Grants.htm (last visited Feb. 9, 2007). "The Connecticut Stem Cell Research Grants-in-
Aid Program was established by the Connecticut General Assembly in June 2005 when it passed" [Connecticut
legislation on stem cell research]". Id. "The legislation appropriates $20 million dollars to support embryonic
and human adult stem cell research through June 30, 2007. In addition, for each of the fiscal years ending June
30, 2008 through June 30, 2015, the legislation specifies that an additional $10 million dollars should be
disbursed to support additional research. In total, at least $100 million in public support will be available over
the next ten years for stem cell research." Id.
26. State of New Jersey Commission on Science & Technology, http://www.state.nj.us/scitech/stemcell/
(last visited Feb. 9, 2007). "A total of $8.5 million dollars in state funds went to support current work at the
Stem Cell Institute of New Jersey in Fiscal Year 2006." Id. "A law signed on January 2, 2004 ... permits
research and use of human embryonic stem cells, germ cells, and human adult cells from any source. It also
requires physicians treating infertility patients to provide these patients with information about donating human
embryos after infertility treatment." Genome News Network, Stem Cells: Policies and Players, http://www.
genomenewsnetwork.org/resources/policiesandplayers/ (last visited Feb. 9, 2007).
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setts27 have passed or are developing, funding measures for stem cell research.
None of these state initiatives, however, compare to California's Proposition 71,
which is the most progressive.
1. California's Proposition 71
In direct response to President Bush's announcement, California voters
passed Proposition 71 in November 2004.28 Proposition 71 made it a constitu-
tional right to conduct stem cell research in California. 9 Proposition 71 allocated
$3 billion, spread over ten years, to establish a new stem cell research institute to
regulate and distribute funding for stem cell research in California. °
Proposition 71 established the California Institute for Regenerative Medicine
(CIRM) "to regulate stem cell research and provide funding, through grants and
loans, for such research and research facilities.",31 CIRM is responsible for
establishing regulatory standards for stem cell research funded by the grants and
loans and managing such research and the development of related facilities.32 In
addition, CIRM is governed by a 29-member Independent Citizen's Oversight
Committee (ICOC), comprised of representatives from California universities,
nonprofit academic and medical research institutions, companies with expertise
33in developing medical therapies, and diverse research advocacy groups.
All covered stem cell lines used in CIRM-funded research must be
"acceptably derived," meaning that donors of gametes, embryos, somatic cells or
human tissue gave voluntary with informed consent and did not receive valuable
consideration.34
Proposition 71 is a good model for federal legislation of stem cell research,
however, it is not sufficient in and of itself. In order for the United States to
succeed in the field of biotechnology, the federal government must consider the
global ramifications of its stem cell policy. To remain competitive with other
27. Daily News Central, Massachusetts Stem-Cell Bill Becomes Law Despite Veto, June 2005,
http://health.dailynewscentral.com/content/view/929/62. "Under previous [Massachusetts] law, scientists who
wanted to conduct human embryonic stem cell research needed to seek the approval of the local district
attorney." Id. The new law removes that requirement, but it gives the state Health Department some regulatory
controls. The bill does not include any funding for the research. Id.
28. George J. Annas, The ABCs of Global Governance of Embryonic Stem Cell Research: Arbitrage,
Bioethics, and Cloning, 39 NEW ENG. L. REV. 489, 496-497 (2005).
29. California Proposition 71, Stem Cell Research, Funding, Bonds: Initiative Constitutional Amend-
ment and Statute: Official Title and Summary, available at http:/lwww.ss.ca.gov/elections/bp-novO4/prop-
71_entire.pdf (last visited Mar. 8, 2008); California Healthcare Foundation, HealthVote.org, Check Up on
Proposition 71-What Happened Since It Passed in November 2004?, http://www.healthvote.org/index.php/
checkup/C28/ (last visited Mar. 8, 2008).
30. Annas, supra note 28.
31. Proposition 71, supra note 29.
32. Id.
33. Id.
34. Id.
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nations in the field of biotechnology, the federal government should examine and
adapt some successful international models. One successful model to consider is
that of Singapore.
B. Singapore Laws
The combination of government funding and laws has earned Singapore a
reputation as a haven for biotechnology freedom. 5 Seeking to diversify its
electronics-dominated manufacturing sector, the government of Singapore
launched the Biomedical Sciences initiative in mid-2000.36 Since 2000, the
Singaporean government has spent $949 million U.S. dollars on biotechnology
research and development, including stem cell research.37 It budgeted another
$900 million over the next five years" and established a $600 million fund to
invest in biotech startups. 39 As a symbol of Singapore's commitment to its
biotechnology initiative, the Singaporeans built a massive research facility called
Biopolis.4° Costing $290 million, Biopolis is a two-million-square-foot, seven-
building complex dedicated to research'
In addition to the liberal funding, Singapore's more favorable and more
tolerant laws on embryonic stem cell research have also helped Singapore's
quick scientific expansion.4 2 The Singaporean cabinet appointed the Bioethics
Advisory Committee (BAC) in December 2000 to examine the potential legal,
ethical, and social issues arising from biomedical research in Singapore.43 The
BAC makes its recommendations to the Steering Committee for Life Sciences,
which oversees the development of biomedical sciences in Singapore." To
balance scientific progress and community values and ethics, the BAC conducted
extensive research and consulted with various local interest groups and the public
in order to understand the people's concerns and views regarding stem cell
research and cloning. In June 2002, the BAC published its recommendations."
35. Wayne Arnold, Singapore Acts as Haven for Stem Cell Research, N.Y. TIMES, Aug. 17, 2006,
http://www.nytimes.con/2006/08/17business/worldbusiness/17stem.htnil?pagewanted= &ei=5088&en=a3268
595bc581 cd7&ex= 1313467200&partner=rssnyt&emc=rss.
36. Id.
37. Id.
38. Id.
39. Bruce Einhorn, Asia is Stem Cell Central, Business Week Online, Jan. 10, 2005, http://www.
businessweek.comlmagazine/content/05_02/b3915052.htm.
40. Paul Smaglik, Singapore: Filling Biopolis, NATUREJOBS, Oct. 16, 2003, available at http://www.
nature.com/nature/j ournal/v425/n6959/full/nj6959-746a.html.
41. Id.
42. Einhorn, supra note 39.
43. Singapore Bioethics Advisory Committee, http://www.bioethics-singapore.org/resources/body_
useful.html (last visited Mar. 4, 2007).
44. Id.
45. Heather L. Fowler, Note, Misapplied Ethical Considerations: U.S. Federal Stem Cell Mandates
Lack Global Focus and Market Foresight, 36 CORNELL INT'L L.J. 521, 531-532 (2004).
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Unlike the U.S. policy, which prohibits the use of federal funding for research
using newly-derived embryonic stem cell lines, 7 the BAC recommended that
human stem cell research and therapeutic cloning should be allowed, but under
strict regulation.49 Similar to the U.S. policy, the BAC recommended a complete
ban on human reproductive cloning. 49 The BAC recommended prioritizing the
source of stem cells available for research.50 First, researchers must use existing
stem cell lines derived from human embryos less than fourteen days old." Then
researchers may derive embryonic stem cells from surplus human embryos
created for fertility treatment less than fourteen days old.52 As a last resort,
researchers may create human embryos but only when the researcher can show
that there is "strong scientific merit in, and potential medical benefit from, such
research; [and] no acceptable alternative exists."53 The BAC also recommended
that "there must be informed consent from the donors of surplus human embryos,
gametes or cells" and in obtaining the consent, "there must not be any
inducements, coercion or undue influence. 54 In addition, the BAC proposed the
adoption of legislative guidelines and the creation of a regulatory body "to
license, control, and monitor all human stem cell research in Singapore."55 In July
2002, the Singaporean government adopted the BAC's recommendations as
Singapore's ethical stance on the subjects of stem cell research, therapeutic
cloning, and reproductive cloning.56 The government appointed the Ministry of
Health to establish regulations "to license, control, and monitor all human stem
cell research conducted in Singapore."57 The Singapore Parliament passed
legislation on September 2004, allowing stem cell research on human embryos
provided that the embryo is less than fourteen days old.58
46. Sylvia Lim & Calvin Ho, The Ethical Position of Singapore on Embryonic Stem Cell Research,
SMA NEWS, Vol. 35 at 21, June 2003, available at http://www.stemcell.edu.sg/docsll7/BAC2-Lim-and-
Ho6.pdf.
47. President Bush, supra note 11.
48. Fowler, supra note 45, at 532.
49. Id.; see also Lim & Ho, supra note 46.
50. Id.
51. Id.
52. Id.
53. Id.
54. Lim & Ho, supra note 46.
55. Fowler, supra note 45, at 532; see also Lim & Ho, supra note 46.
56. Lim & Ho, supra note 46; see also Singapore Bioethics Advisory Committee, available at
http://www.bioethics-singapore.org/ about/body-milestone.html.
57. Tony Keng Yam, Remarks by Dr. Tony Keng Yam, Deputy Prime Minister and Minister for
Defence at the Opening Ceremony of the Conference on "Beyond Determinism and Reductionism: Genetic
Science and the Person" (July 17, 2002) (transcript available at http://www.biomed-singapore.com/bms/sg/en-
_uk/index/newsroom/speeches/2002/speech_by-drjtony.html).
58. Republic of Singapore, Human Cloning and Other Prohibited Practices Act, 2004, No. 35 (2004)
(Sing.); see also United Kingdom Department of Health, UK Stem Cell Initiative, http://www.advisory
bodies.doh.gov.uk/uksci/global/singapore.htm (last visited Mar. 4, 2007).
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III. THE SCIENCE AND BENEFITS OF HUMAN EMBRYONIC STEM CELLS
A. What are Stem Cells?
Stem cells are unspecialized cells found in all multi-cellular organisms that
are capable of renewing themselves through cellular division and developing into
many types of specialized cells in the body. 9 There are three types of mammalian
stem cells: embryonic stem cells, adult stem cells, and cord blood stem cells.
6
0
Adult stem cells are extracted from organs and tissue, such as the skin, liver,
brain, and bone marrow.6' In the human body, adult stem cells repair and
replenish damaged or dying cells. 62 Like all other types of stem cells, adult stem
cells can divide and renew themselves. 63 However, unlike an embryonic stem
cell, an adult stem cell also has a limited capacity for cellular differentiation. 64 It
can only become the cell type of its origin and a small subset thereof.65 Therefore,
66
a skin-forming stem cell will develop into skin cells, not brain or liver cells.
Embryonic stem cells are stem cells that can be found in a blastocyst, a ball
of cells that develop four or five days after an egg is fertilized. 6 Generally,
embryonic stem cells are extracted from donated embryos that have been created
during in vitro fertilization treatment, but ultimately not used.66 Unlike adult stem
cells, embryonic stem cells are pluripotent, meaning that they are unspecialized
69
and can develop into virtually any type of cell in the body. In addition to
pluripotency, embryonic stem cells are capable of self-renewal, meaning that
they can go through cellular division for an extended period of time while staying
in an undifferentiated state.7°
A stem cell line is a culture of identical cells that originated from a single
stem cell.7 A stem cell line is created when a stem cell is removed from the body
59. Proposition 71, supra note 29.
60. International Society for Stem Cell Research, Frequently Asked Questions on Stem Cell Research,
available at http://www.isscr.org/science/ISSCR-FAQ.pdf (last visited Mar. 8, 2008).
61. Proposition 71, supra note 29.
62. THE NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES,
STEM CELL INFORMATION, http://stemcells.nih.gov/info/basics/basics4.asp (last visited on Mar. 8, 2008).
63. Id.
64. Id.
65. Proposition 71, supra note 29; Stanford School of Medicine, Stem Cell Primer, http://stanmed.
stanford.edu/2004fall/story-images/primer.pdf (last visited Mar. 8, 2008).
66. Stanford School of Medicine, supra note 65.
67. Leslie Leazer, "Brother Can You Spare a Cell?" The Ethical Debate and Moral Minefield
Surrounding Stem Cell Research on US and International Law, 13 CURRENTS: INT'L TRADE L.J. 38, 39 (2004).
68. Press Release, The White House, supra note 13.
69. Rosario M. Isasi et al., Legal and Ethical Approaches to Stem Cell and Cloning Research: A
Comparative Analysis of Policies in Latin America, Asia, and Africa, 32 J.L. MED. & ETHICS 626, 628 (2004).
70. Allison C. Ayer, Comment, Stem Cell Research: The Laws of Nations and a Proposal for
International Guidelines, 17 CONN. J. INT'L L. 393, 396 (2002).
71. Stanford School of Medicine, supra note 65; Denise Stevens, Comment, Embryonic Stem Cell
Research: Will President Bush's Limitation on Federal Funding Put the United States at a Disadvantage? A
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and isolated and cultured in a Petri dish.2 The stem cell divides and produces
multiple copies of itself."
B. Potential Benefits of Human Embryonic Stem Cell Research
Embryonic stem cells are of greater interest to scientists than adult stem cells
because of their unique properties of pluripotency and self-renewal. 4 In addition,
scientists prefer to work with embryonic stem cells because adult stem cells may
not exist for all cell types, they are more difficult to isolate and purify, and they
may be able to only duplicate themselves a limited number of times."
Human development has proven to be a complex and difficult area of study
for scientists. 76 Because embryonic stem cells can develop into virtually any cell
type in the body, embryonic stem cell research offers scientists greater insight
into the mysteries of human development.] Through stem cell research, scientists
hope to unlock some of these mysteries." For example, an understanding of early
human development could potentially lead to prevention and treatment of
infertility and birth defects.7 9
Stem cell research also has shown great potential toward the development of
therapies and cures for many diseases and injuries that are incurable today,
including diabetes and spinal cord injuries.80 Because embryonic stem cells have
the capability of duplicating themselves and differentiating into virtually any cell
type in the body, scientists believe that they have the potential to replace diseased
or damaged cells, tissues, and organs." The ability to replace faulty cells could
cure diseases that are caused by a defect in just a few cells, such as Parkinson's
disease.82 Similarly, the ability to grow human tissues and organs in a laboratory
may be the answer to organ donor shortages and host body rejection of donated
organs.83
Embryonic stem cell research still has a long way to go and practical
application will only be possible though additional research and experimen-
Comparison Between U.S. and International Law, 25 HOus. J. INT'L L. 623, 627 (2003).
72. Christopher Scott Pennisi, Note, More on Moore: A Novel Strategy for Compensating the Human
Sources of Patentable Cell-Line Inventions Based on Existing Law, I I FORDHAM INTELL. PROP. MEDIA & ENT.
L.J. 747, 748 (2001).
73. Ayer, supra note 70 at 397.
74. Fowler, supra note 45 at 526-527.
75. Stevens, supra note 71 at 632.
76. Ayer, supra note 70 at 397.
77. Id.
78. id.
79. Isasi et al., supra note 69; University of Wisconsin, Embryonic Stem Cells, http://www.news.wisc.
edu/packages/stemcells/facts.html#I (last visited Jan. 15, 2006).
80. See, e.g., University of Wisconsin, supra note 79.
81. Id.
82. Id.
83. Id. Leazer, supra note 67.
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tation. ' Through research and experimentation, scientists hope to understand the
mechanism of cell differentiation. s5 This understanding will enable them to direct
cells to become a particular type of tissue or organ.s Understanding this process
will also allow scientists to control differentiation of stem cells so they will be
therapeutically effective and be useful in the field of medicine.87
IV. BIOETHICAL CONCERNS SURROUNDING HUMAN EMBRYONIC
STEM CELL RESEARCH
Embryonic stem cell research is controversial because it involves the
destruction of human embryos."8 This destruction raises questions regarding the
value of human life and the legal status of the embryo. 9 Another concern of those
who oppose stem cell research is the possibility that stem cell research will lead
to human cloning.9
The debate over stem cell research puts religious leaders in opposition with
the scientific community. 9' While human embryonic stem cell research has the
potential to lead to cures for millions of people afflicted with severe illnesses not
curable today, it is controversial because it involves the use and destruction of
human embryos.92
Generally, stem cells are extracted from embryos that are no more than
fourteen days old.93 This extraction of stem cells destroys the embryo.94 The
debate about the destruction of the embryo parallels that of the abortion debate. 95
Most concerns revolve around the question "when does life begin?" 96 Central to
the debate is the legal status of the embryo.97 The Catholic Church and other
84. See, e.g., University of Wisconsin, supra note 79.
85. Id.
86. Id.
87. Id.
88. Stevens, supra note 71, at 630-632.
89. Id. at 630.
90. Id. at 634.
91. Berger, supra note 10.
92. Stevens, supra note 71, at 630-632.
93. Id. at 630; THE NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN
SERVICES, STEM CELL INFORMATION, http://stemcells.nih.gov/info/basics/basics3.asp (last visited Feb. 15,
2007); Fowler, supra note 45, at 532. See also Lim & Ho, supra note 46. Ethics commission in several countries
including the United Kingdom (Warnock report), the U.S. (NIH Human Embryo Research panel 1994),
Australia, and Denmark have approved research on the human embryo up to fourteen days in development.
Until fourteen days, it is more correctly called a "pre-embryo" because the embryo has not differentiated into
tissues. At fourteen days, a structure called the "primitive streak" appears which later becomes the brain and
spinal cord. Stem Cell Research, Singapore, Human Embryonic Stem Cells: Science and Ethics,
http://www.stemcell.edu.sg/docs/17/BACI-Bongso7.pdf (last visited on Mar. 8, 2008).
94. Stevens, supra note 71, at 630.
95. Id. at 630-631.
96. Id.
97. Id. at 630.
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religious groups believe that life begins at conception.9" Therefore, they believe
that the destruction of an embryo in order to harvest the stem cells is murder.99
The current U.S. policy is based on this belief.'° President Bush based his
decision partly on his belief that federal funds should not be used to support the
"further destruction of human embryos."'' "The federal government... believes
that nascent human life ought not [to] be violated, and will not contribute to,
participate in, or promote or reward its violation."
'0 2
Another major concern with stem cell research is that the research could lead
to human cloning.' 3 Pro-life advocates are against the use of therapeutic cloning
to produce embryos solely for the extraction of stem cells.'0 They are concerned
that this type of cloning creates life only to destroy it for the sake of research."5
The pro-life advocates believe that the moral cost of therapeutic cloning far
outweighs the potential benefits that may result from stem cell research.'
6
The debate surrounding the issue of cloning is often clouded with confusion
between therapeutic and reproductive cloning.' 7 "Therapeutic cloning" is the
cloning of human embryos solely for the purpose of producing stem cells. 1
8
Therapeutic cloning is different from "reproductive cloning," the kind of cloning
used to produce Dolly the sheep.' ° In reproductive cloning the cloned embryo is
allowed to develop to term, resulting in a genetic twin." ° Most countries have
legislation or are drafting legislation that forbids human reproductive cloning.'
Certain groups, including the Right to Life Committee, oppose therapeutic
cloning as a means to produce embryos for stem cell research." 2 They consider
the practice of therapeutic cloning as "creating human embryos for the sole
purpose of killing them and harvesting their cells."" 
3
98. Id. at 63 1.
99. Richard Posner, The Economics of Stem-Cell Research, The Becker-Posner Blog, Aug. 20, 2006,
http://www.becker-posner-blog.com/archives/2006/08/the-economics-o_5.html (last visited Mar. 9, 2008).
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103. Stevens, supra note 71, at 634.
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Another concern is that embryos will be sold and bought like chattel."' Many
fear that women will be exploited to donate their eggs or embryos for research by
offering them monetary inducements."5 The National Institutes of Health (NIH)
expressly "prohibit[s] the use of inducements, monetary or otherwise, for the
donation of the embryo." 6 There must also have been a clear separation between the
fertility treatment and the decision to donate embryos for this research."' 17 Similarly,
Singapore has guidelines prohibiting the sale of embryos and the guidelines require
the informed consent of the donors."8
Regardless of the merits of these moral contentions raised by religious groups
and conservatives, the underlying impact of the current U.S. policy has been quite
severe on the United States' scientific and economic development.
V. EFFECTS OF U.S. POLICY ON THE U.S. BIOTECHNOLOGY INDUSTRY, THE
ECONOMY AND THE HEALTH OF AMERICANS
The federal policy has had a substantial impact on the U.S. biotechnology
industry and the economy. " 9 It has caused many research delays, putting American
researchers at a disadvantage compared to researchers in other countries. The
policy also causes "brain drain" and loss of tax revenues for the United States. 2 if
the United States continues to lag in stem cell research, Americans too will be
impacted by the current policy because it is probable that they will have to wait
longer and pay more for the therapies the result from stem cell research.'
2
A. Obstacles in Research Threaten the United States Position as World-Leader in
Biotechnology
Although the first human embryonic stem cells were isolated in the United
States, the majority of new embryonic stem cell lines are now being created
114. Taiwo A. Oriola, Ethical and Legal Issues in Singapore Biomedical Research, PAC. RIM L. &
POL'Y J. 497, 521-522 (2002).
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RESEARCH GUIDELINES, http://www.hhs.gov/news/press/2001pres/01 fsstemcell.html (last visited Mar. 8, 2008).
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122. Id. at 529.
Global Business & Development Law Journal / Vol. 21
123
overseas. This is a concrete sign that the United States is losing its position as
world leader in biotechnology, specifically, in stem cell research.'
24
When President Bush prohibited federal funding of research using human
embryonic stem cell lines created after August 9, 2001, the NIH thought that
there would be more than sixty available stem cell lines for research. 5 Today,
however, it is clear that there are only twenty-two usable cell lines eligible for
federal funding. 2 6 And this number will only decrease as the cell lines age.1
27
With each division of the stem cells, the likelihood of genetic mutations in the
stem cell line is increased.' In contrast, there are over 100 newly-derived cell
lines available to the world's researchers that are off-limits to U.S. researchers
receiving federal funding.
2 9
The off-limits stem cell lines created since President Bush's announcement
include some cells that are easier to use and cells that are tailored for the study of
a particular disease. 30 Some of the new stem cell lines are also safer for patients
because all of the stem cell lines that currently qualify for federal funding are
grown on a layer of mouse cells. 3 ' The layer of mouse cells, called a "feeder
layer," nourishes the human cells, but it makes the cell lines unsuitable for use on
humans because they could transmit mouse-borne viruses."' The mouse cells
could also lead to an immune response and rejection when used on humans.' 3
Laboratories in Singapore recently isolated stem cells lines that used human skin
cells instead of mouse cells as a feeder layer.3 4 In contrast, only one American
123. Gareth Cook, U.S. Stem Cell Research Lagging without Aid, Work Moving Overseas, Boston
Globe, May 23, 2004, available at http://www.boston.com/news/science/articles/2004/05/23/us stem-cell_
researchlagging?mode=PF.
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FUNDING OF RESEARCH ON HUMAN EMBRYONIC STEM CELLS, http://stemcells.nih.gov/staticresources/research/
registry/PDFs/EligibilityCriteria.pdf (last visited Feb. 17, 2007).
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debate, http://publicaffairs.uth.tmc.edu/hleader/archive/RESEARCH/2007/stemcell-0206.html.
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http://www.isscr.org/science/faq.htm (last visited Feb. 19, 2007).
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laboratory has accomplished this-Susan Fisher's California laboratory.'35
Fisher's laboratory does not receive federal funding due to its work on ineligible
stem cell lines and is partly funded by the California-based biotech Geron
Corp. 36 None of these new stem cell lines, including Fisher's, can be used by
American researchers who are receiving federal funding.'37
As overseas laboratories continue to develop new stem cell lines, they are
learning more from each new line.'38 Human embryonic stem cells are generally
difficult to work with and handle.'3 9 By deriving each new stem cell, a researcher
gains new insight on the stem cell biology and this allows the researcher to gain
some new practical skill.' 40 Scientists overseas and privately-funded American
scientists are making advances that they can share freely with each other, but
they cannot share these advancements with federally-funded American
scientists. '4' The result is that, with each new line, federally-funded American
researchers fall further behind.'42 The end result of the U.S. federal policy is that
American researchers are being placed at a disadvantage to their overseas
counterparts. 143
For many countries and foreign scientists, the U.S. restrictions on stem cell
research represent an opportunity for their biotechnological programs to
benefit.'" Governments around the world are recognizing this opportunity, and a
number of them, including Singapore, are capitalizing on it.'4 5 As a result,
Singapore is emerging as a powerhouse in the biotechnological field.'
46
B. Brain Drain of Top U.S. Researchers and Scientists
Many of the world's top scientific researchers work at universities in the
United States, but due to the federal policy, they are largely unable to work on
human embryonic stem cells and are thus unable to move forward with their
research. '47 The federal policy severely constrains the research because scientists
are unable to work with newly-created stem cell lines, which are easier to work
with and are safer for use in humans.'4 1 In addition, access to the stem cell lines
135. Id.
136. Id.
137. Id.
138. Id.
139. Id.
140. Id.
141. Id.
142. Id.
143. Id.
144. Id.
145. Id.
146. Id.
147. Id.
148. Id.
Global Business & Development Law Journal / Vol. 21
that are federally-approved is a slow and frustrating process, causing huge delays
in research. 
49
Universities are similarly affected, as they are likely to have more difficulty
attracting foreign scientists interested in stem cell research.'50 Researchers who
might otherwise be interested in the field are avoiding it because of the risk of an
uncertain future. 5 ' And some scientists worry younger scientists, who do not'
have an established laboratory in the United States, will move abroad to study
stem cells. 2
Others researchers have moved, or plan to move, their laboratories to
countries, like Singapore, with less restrictive regulations on stem cell research.'53
The current global exchange in the field of biotechnology makes it easier for
those subject to restrictive regulations in one venue to move to another less
restrictive venue. 54 This phenomenon is often referred to as legal or regulatory
arbitrage, where "those subject to the law of any one national jurisdiction may
alter the location of their activities in order to take advantage of the legal [or
regulatory] difference."'55 Researchers and pharmaceutical companies may
choose to operate in a particular venue due to the greater legal protection the
venue provides, for example, through strong patent law protection. 1 6 Likewise,
they may choose a venue based on laws that are favorable to their endeavor, such
as, laws that allow human embryonic stem cell research.5 7 The decision on where
to establish a base of operations may also involve non-legal decisions, such as
skill of the labor force, availability of funding, and confidence in the financial
systems.'58 Singapore consciously made regulatory decisions that encourage
scientific research and innovation as a means to their goal of becoming a global
hub for biomedical research. 59
With the help of generous salaries, lofty titles, and favorable laws,
Singapore's Biopolis is seeing an influx of big names from all over the world,
including from the United States.' 6° Luminaries currently working at Biopolis
include Dr. Edison Liu, who was the former Director of Clinical Science at the
U.S. National Cancer Institute; 6' Alan Colman, the British Nobel laureate who
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was part of the group that cloned Dolly the sheep;' 2 and Neal G. Copeland and
Nancy A. Jenkins, the prominent American husband-and-wife cancer research
team. 63 Singapore is driven to attract top researchers from around the world to
help in the effort to expand its scientific infrastructure and in so doing, has
become internationally competitive in the field of biotechnology.
'64
In Singapore, researchers are provided an attractive environment for research
with new laboratories and plenty of funding, and there is less governmental
scrutiny than in the United States.' 65 Singapore has taken advantage of the U.S.
federal policy by anticipating and meeting the demands that such policies
create. 66
C. Effects of U.S. Policy on Revenues and Taxes
Economic growth depends on science because science leads to technology,
and technology leads to productivity. 67 The current U.S. policy restricting human
embryonic stem cell research is harming the vitality of the U.S. economy by
slowing down the scientific research of this field. 68 The current policy also has
other more direct effects on the economy.' 69 First, the current policy is a factor in
the decision of many companies to leave the United States and move offshore. 7°
Second, it deters private investment in the biotechnology field.' 7' Third, the
prohibition of use of federal funds for research with ineligible stem cell lines
causes costly duplication of work, equipment, and facilities for researchers
receiving both federal and private funds."'
The current policy puts the United States behind other countries, including
Singapore, in the science of stem cell research. 73 Although knowledge flows in
the global scientific community, the people who actually do the research gain a
better and deeper understanding of the science than those who merely read about
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it in a scientific journal.'74 Scientists are hopeful that stem cell research will lead
to technology in the form of therapies and cures for various diseases.'75 These
therapies and cures could potentially result in major business development in the
near future once they go into main production.'76 If major breakthroughs occur in
other countries, it may be difficult for American scientists to keep pace with the
discovering countries and the new technology may not be readily available to
American scientists.
Another direct effect of the current policy is that some biotech and
pharmaceutical companies are leaving the United States.'7 7 Companies that find
the current policy too restrictive are moving offshore to do their research.'78 This
movement offshore has a real effect on the U.S. economy. 79 When the companies
move, they take with them revenues, tax dollars, and jobs.'80 "In 2001, biotech
companies nationally reported net sales of $567 billion, operating income of
$100.5 billion, capital expenditures of $29.5 billion and the employment of
approximately 1.1 million people."' 8 ' This movement offshore not only affects
the biotech industry, but also affects other industries, such as financial
institutions, marketing firms, construction, and legal services, causing a ripple
effect in the economy.'8 2
The current U.S. policy also deters investment in biotechnology by private
enterprises'83 and hinders the formation of partnerships between countries.184 The
current policy effectively leaves the regulation of stem cell research to the
individual states. '85 This type of policy makes for a fragmented and unstable
environment that is not attractive to enterprises and investors. 
86
The federal policy also prohibits researchers working on ineligible stem cell
lines from using federally funded facilities.187 This wastes resources because the
states have to build separate laboratories to conduct such research.' 88 Eighty-six
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percent of state funding for stem cell research has gone to building facilities,
purchasing equipment, and training scientists.
89
In contrast, Singapore launched a biotechnology initiative in 2000, which
encourages scientific research, including stem cell research.' 9 To attract
pharmaceutical companies, Singapore is using the same combination of land
subsidies, '9' tax holidays, and incentives it used in the past to attract the world's
biggest electronics manufacturers.' 92 Companies like Merck, Pfizer, and Shering-
Plough have set up shop in Singapore and now generate $11.4 billion in annual
revenue, which accounts for 5 percent of Singapore's economy. 1
3
Singapore wants the pharmaceutical companies not only to make drugs, but
to conduct drug research and development as well. 94 To persuade the
pharmaceutical companies to conduct the research and development, Singapore
offered land subsidies 95 and subsidized up to thirty percent of their building
costs. 196 More than thirty companies responded including the Swiss drug
company Novartis, which opened the Institute for Tropical Diseases in Singapore
to develop drugs against tuberculosis and the dengue virus. 97
D. Effects of U.S. Policy on Health and Welfare
"Estimates suggest that more than 3,000 people die every day in the United
States from diseases that could be treatable as a result of stem cell research,
including Alzheimer's, Parkinson's, diabetes, multiple sclerosis, heart disease,
stroke and spinal cord injury."'' 9 8 Many scientists believe that stem cell research
has the potential to revolutionize medicine and improve the quality and length of
life.'99 As a result of the current U.S. policy, Americans will have to wait longer
and pay more for new medical treatments that are developed as a result of stem
cell research.2°° In restricting stem cell research, the federal government has acted
narrow-mindedly by failing to adequately consider the potential benefits of stem
cell research.2°'
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If the United States does not change its policy and researchers in other
countries begin to make progress, the United States will lose out on the potential
gains that stem cell research promises . 2 The benefits gained from scientific
research will accrue to the country that backed and funded it.203 If a cure is first
developed in a foreign country, the U.S. government and U.S. researchers may
have little, if any, access to it.20° Worse, the American people may not be able to
benefit from the newly developed cure immediately because they may not have
access to it.205 Even if access to the newly developed cure is not an issue,
Americans may have to pay more for it.206 Market forces and foreign
governments may then dictate the course of science and medicine without regard
to the overall public benefit . 7
To best encourage scientific development and to promote the health and
welfare of the American people, all avenues for funding and developing cures
and treatments should be available to the scientific community. 0 This will allow
researchers to focus on their research, instead of worrying about funding or
keeping their privately-funded research separate from their federally-funded
209
work.
The U.S. government is traditionally the largest source of funding for
scientific research.20 Without its backing of stem cell research, it not only hinders
progress in the United States, but it also slows down the global scientific
progress.2 ' Federal funding and federal legislation are the best way to guarantee
that stem cell cures and treatments are developed. 212 It is the best way to ensure
that research is done with the public welfare as the main goal.23 It is also the best
way to ensure that the research is done ethically.2 4 Federal legislation alone,
however, is not sufficient since the research laboratories can be moved from one
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venue to another. The public will be best served if there is a concerted inter-
national effort surrounding stem cell research.2 5
VI. PROPOSED SOLUTION
The scientific community and public are hopeful that stem cell research will
lead to cures and treatments for many diseases)' 6 However, it will probably take
many years before cures and treatments are produced." ' Basic research on stem
cells needs to be done to investigate whether such cures and treatments are
possible as scientists hope.2 8 Stem cell research, however, is plagued with many
controversies and the research is slowed down by debate, including the legal
status of an embryo and cloning.2 9
The international community needs a uniform guideline to direct and regulate
stem cell research. 220 Drafting an international guideline will ease some of the
concerns and issues raised by stem cell research. 22' An international agreement is
also the best way to ensure that stem cell research is conducted ethically and
within internationally accepted standards.
A. The United States Should Take the Lead in Drafting an International
Guideline
The U.S. government should take the initiative and assist in the creation of an
international guideline governing stem cell research.2 22 The United States,
traditionally a world leader in the field of biotechnology, has the credibility,
experience, and resources to lead and oversee the drafting of the guideline.223
Before the United States can take a lead role in creating the international
guideline, however, it needs to first enact domestic legislation to regulate stem
224
cell research, on which an international guideline would later be based. The
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lack of a uniform federal law only fosters disparities among the states."' By
enacting its own uniform legislation first, the United States can serve as a
"laboratory" for the international community and test some of the rules before
they are implemented on a global scale.
B. United States Domestic Stem Cell Law
1. The United States Should Incorporate Aspects of California's
Proposition 71
In drafting the domestic legislation, the United States should incorporate
some aspects of California's Proposition 71. The legislation should follow
California's lead by making embryonic stem cell research a constitutional right
and by prohibiting the funding of human reproductive cloning research.226
Proposition 71 established the CIRM "to regulate stem cell research and provide
funding, through grants and loans, for such research and research facilities. 227
The U.S. legislation should incorporate a similar provision that would delegate
the regulation of stem cell research and provision of funds to a federal agency
similar to CIRM. Such an agency may establish regulatory standards for
federally-funded stem cell research within prescribed federal laws.
CIRM is also governed by the ICOC, which is comprised of representatives
from California universities, nonprofit academic and medical research
institutions, companies with expertise in developing medical therapies, and
diverse research advocacy groups.22s The federal government could similarly
assign an oversight committee made up of various universities, experts in the
field, and advocacy groups that would act as a check on the regulatory board and
ensure that federally-funded stem cell research is carried out within federally
prescribed standards.
In California, all covered stem cell lines used in CIRM-funded research must
be "acceptably derived," meaning that donors of gametes, embryos, somatic cells
or human tissue gave voluntary with informed consent and did not receive
valuable consideration. 29 The federal law should similarly include a provision
that requires the donor's voluntary and informed consent. In addition, it should
make it illegal to induce, coerce, or unduly influence donors into donating
embryos.
Although Proposition 71 is a good model for federal legislation, it does not
sufficiently provide for international relations and ramifications of stem cell
research. In order for the United States to continue to be competitive in the field
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of biotechnology, the federal legislation should also incorporate aspects of some
of the more successful international models available, such as Singapore.
2. The United States Should Adopt Some Aspects of Singapore's Laws
The U.S. legislation should follow Singapore's lead with both its laws on
stem cell research and its policies that foster the growth of the biotechnology
industry in its country. Like Singapore, the U.S. federal law should prioritize
permissible sources of stem cells.23° It should list whether existing stem cell lines,
surplus human embryos, aborted fetuses, or therapeutically cloned embryos are
permitted for use in research. The legislation should also include any
requirements that must be fulfilled prior to experimentation, such as approval by
the regulatory agency before therapeutic cloning can be done. Singapore's laws
state "[w]here permitted, [embryonic stem] cells should be drawn from sources in
the following order: (1) existing [embryonic stem] cell lines, originating from
[embryonic stem] cells derived from embryos less than 14 days old; and (2)
surplus human embryos created for fertility treatment less than 14 days old.,
23
"The creation of human embryos specifically for research can only be justified
where (1) there is strong scientific merit in, and potential medical benefit from,
such research; (2) no acceptable alternative exists; and (3) on a highly selective,
case-by-case basis, with specific approval from the proposed statutory body. 232
Similar to California, Singapore's laws include an informed consent
provision.233 It states that "[flor derivation and use of [embryonic stem] cells,
there must be informed consent from the donors of surplus human embryos,
gametes or cells. 2 34 "In obtaining consent from donors of cells, gametes, tissues,
[fetal] materials and embryos, the information provided to the donors must be
comprehensive, and there must not be any inducements, coercion or undue
influence.235
In addition, U.S. legislation must provide enough funding to attract business
and scientists to the come and stay in the United States. The federal government
must provide enough funding to stem cell research to attract top scientists. The
federal legislation must also be less restrictive of stem cell research and assure
some stability. The federal government must offer an attractive environment for
researchers, pharmaceutical companies, and private investors. It can follow
Singapore's lead, by offering incentives to companies to do business in the
United States.
230. Fowler, supra note 45, at 532; Lim & Ho, supra note 46.
231. Lim & Ho, supra note 46.
232. Id.
233. Id.
234. Id.
235. Id.
Global Business & Development Law Journal / Vol. 21
C. International Guideline
Drafting an international guideline while the research is at its early stages is
especially important because the preliminary stages of stem cell research are very
costly and time consuming.236 An international guideline will encourage the
sharing of basic research among international laboratories, speeding up the
progress in the field and encouraging collaboration."' It will also give everyone
involved an interest in any potential advances developed from the research.238
Moreover, an international guideline will eliminate regulatory arbitrage.239 In
addition, uniform legislation may ease some of the concerns that are at the
forefront of the stem cell research controversy. Some international norms that are
taking shape and can be incorporated into an international set of guidelines
include the ban of on human cloning. Furthermore, the international guideline
should include penalties and a mechanism for enforcement, such as a board of
directors composed of a member from each participating country.24 0 By including
an enforcement provision everyone is forced to abide by the guidelines, and it
ensures that the research will be done ethically and in accordance with
internationally accepted standards.24'
While there are many differences in human embryonic stem cell initiatives
and policies between countries, there are a few commonalities that can be used to
shape an international set of guidelines. Despite differences in culture, religion,
and social norms among various countries, it is possible to find some overlap that
could be used as the basis for the guidelines. These commonalities include: the
goal of research is to improve quality of health care and improve quality of life;
the need for voluntary and informed consent; minimizing harms from the
research; banning on human reproductive cloning; and access to the benefits
from the research. The challenge in drafting international guidelines on human
embryonic stem cell research is the balancing of these goals.
1. Limitations on Research on Human Embryos
There is agreement that limitations are necessary on embryonic stem cell
research. Such limitations are a means of addressing bioethical concerns such as
inappropriate ways of obtaining embryos, inappropriate uses of embryos, and
cloning. Limits represent an acknowledgement that some public fears are present
about potential ramifications of such research. Limits also serve to set boundaries
236. Ayer, supra note 70, at 414.
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and recognize that human embryos are distinct from other human tissue.
Singapore allows human embryonic stem cell research under strict regulation.242
Therefore, international guidelines for stem cell research should have clearly
defined limitations.
A common limitation imposed on the use of human embryos for research is
the need to obtain informed consent from the donors of the embryos. The consent
should include specific disclosure of the nature of the research in which the
donated embryos are to be used. Securing the specific informed consent of the
donors respects their personal wishes about disposition of the embryos.
Singapore requires that "there must be informed consent from the donors of
surplus human embryos, gametes or cells" and in obtaining the consent, "there
must not be any inducements, coercion or undue influence.,
243
2. Sources of Human Embryonic Stem Cells
The United States and the international community can adopt a rule similar
to that employed by Singapore which prioritizes the sources of stem cells.
Singapore's laws require researchers to first use existing stem cell lines derived
from human embryos less than fourteen days old.244 Then researchers may derive
embryonic stem cells from surplus human embryos created for fertility treatment
less than fourteen days old.24' As a last resort, researchers may create human
embryos but only when the researcher can show that there is "strong scientific
merit in, and potential medical benefit from, such research; [and] no acceptable
alternative exists. 246
3. Ban on Human Cloning
Most countries, including the United States and Singapore, have a complete
ban against human reproductive cloning.2 7 Therefore, human reproductive
cloning should be addressed, if not banned, by the international guidelines.
4. Creation of a Board and Enforcement Provision
The Singaporean government appointed the Ministry of Health to establish
regulations "to license, control, and monitor all human stem cell research
conducted in Singapore. 248 California's Proposition 71 established the CIRM to
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regulate stem cell research.249 Similar to Singapore and California, the inter-
national guidelines should establish an oversight committee that has the authority
to regulate and enforce the rules of stem cell research to ensure that it is done
within the permissible guidelines of bioethics.
VII. CONCLUSION
Preliminary findings suggest that stem cell research is the most promising
avenue for finding cures and treatments for many debilitating diseases that afflict
millions of people worldwide. The U.S. government must reevaluate its current
policies that restrict human embryonic stem cell research. The United States must
expand stem cell research support and funding or face being technologically and
economically disadvantaged. If the United States does not lift restrictions on stem
cell research imposed by President Bush, American scientists will not be able to
fully explore the potential of stem cell research. The current U.S. policy puts the
health of millions of Americans at risk. The United States cannot afford to lose
its top scientists and researchers to other countries, like Singapore, which
encourages and funds their research. The United States cannot risk not having
access to new treatments and therapies that will inevitably be discovered through
stem cell research.
The United States has a long and proud record of being a leader in science
and medicine. The United States also has a long and proud record of establishing
a high standard of ethics in science and medicine. The United States must take a
lead role in the international arena to ensure that the research is conducted
ethically and for the greatest public good. This can only be effectuated by
enacting domestic legislation that can be harmonized with the rest of the world
and with international guidelines.
The U.S. government should not lose sight of the ultimate goal of stem cell
research-to improve the quality of human lives. Although the debates continue
about "when does life begin?" it is important for to realize that it is not only the
life of an embryo that must be considered; consideration must also be given to
those already living. The benefits of stem cell research substantially outweigh the
costs of the research and it is thus important that we create guiding principles and
requirements so that stem cell research develops in the most effective and
beneficial way possible.
249. Proposition 71, supra note 29.

